Cargando…
Increasing Polarity in Tacrine and Huprine Derivatives: Potent Anticholinesterase Agents for the Treatment of Myasthenia Gravis
Symptomatic treatment of myasthenia gravis is based on the use of peripherally-acting acetylcholinesterase (AChE) inhibitors that, in some cases, must be discontinued due to the occurrence of a number of side-effects. Thus, new AChE inhibitors are being developed and investigated for their potential...
Autores principales: | Galdeano, Carles, Coquelle, Nicolas, Cieslikiewicz-Bouet, Monika, Bartolini, Manuela, Pérez, Belén, Clos, M. Victòria, Silman, Israel, Jean, Ludovic, Colletier, Jacques-Philippe, Renard, Pierre-Yves, Muñoz-Torrero, Diego |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6017698/ https://www.ncbi.nlm.nih.gov/pubmed/29534488 http://dx.doi.org/10.3390/molecules23030634 |
Ejemplares similares
-
Undifferentiated and Differentiated PC12 Cells Protected by Huprines Against Injury Induced by Hydrogen Peroxide
por: Pera, Marta, et al.
Publicado: (2013) -
Huprines as a new family of dual acting trypanocidal–antiplasmodial agents
por: Defaux, Julien, et al.
Publicado: (2011) -
Clock/Sleep-Dependent Learning and Memory in Male 3xTg-AD Mice at Advanced Disease Stages and Extrinsic Effects of Huprine X and the Novel Multitarget Agent AVCRI104P3
por: Giménez-Llort, Lydia, et al.
Publicado: (2021) -
Protective Role of a Donepezil-Huprine Hybrid against the β-Amyloid (1-42) Effect on Human Erythrocytes
por: Zambrano, Pablo, et al.
Publicado: (2021) -
Myasthenia gravis
por: Juel, Vern C, et al.
Publicado: (2007)